Dr. Cannon is a past Judah Folkman Scholar in Residence and the Founder of BioStar Capital and BioStar Ventures now investing in Fund V. He is the past Founder and President of the Cardiac and Vascular Research Center of Northern Michigan and he has received recognition as one of “Americas Top Cardiologists” multiple years by the Consumers Research Council of America. He has served on the National Scientific or Medical Advisory Board or Speakers Bureau for Medtronic, Abbott, Boston Scientific, and Edwards Life Sciences, as well as other pharmaceutical or medical device companies from time to time. He is an innovator with patents previously licensed in the medical device field and has served on the BOD of Corindus Vascular Robotics (CVRS: NYSE ), CardioVascular Ingenuity, SETAGON, Amplitude Vascular Systems and REVA Medical. He has lectured and performed live cases throughout the word at the Montreal Heart Institute, Singapore, Japan and Paraguay where he performed one of the first trans -catheter aortic valve replacements in the world and later sold the BioStar company (AortX) to Hansen Medical. He is the co-moderator of the Shark Tank for medical devices sponsored by the CRF (The Columbia Research Foundation) and was the Founder and President of the Cardiac and Vascular Research Center in Northen Michigan.

Kate Rumrill is a seasoned executive, with 30 years of extensive experience in the Medical Device and Pharmaceutical Industry. She began her career as a Toxicologist with companies such as Sterling Winthrop and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to VP. Most recently, Kate was the President and CEO of NeoSync, Inc., a clinical stage company, developing novel non-invasive neuromodulation devices in the CNS space. Prior to that, she held the position of Vice President, Global Medical Affairs with Covidien’s Peripheral Vascular Division. She has extensive experience in product development and new product launches, most notably through her time at Covidien and Eli Lilly & Company. Kate holds a BS degree in both Biology and Psychology from the State University of New York.

Nate Harrington joined Philips in 2011 and is a Managing Partner at Philips Corporate Ventures, responsible for its Image Guided Therapy (IGT) investments. He currently serves on over a half dozen of the portfolio’s boards; previous director positions include Corindus Vascular Robotics (CVRS) and Affera. Prior to moving to Philips Ventures in 2021, Nate was the Head of Business Development for the IGT business following the acquisition of Volcano and, in that capacity, oversaw acquisitions of Spectranetics, Cardioprolific, EPD, Vesper Medical and led investments in various start-ups currently in the IGT portfolio.
Prior to Philips, Nate worked over 8 years at Boston Scientific Corporation where he held various roles in both product management for Peripheral Interventions division and business development for the Cardiac Rhythm & Vascular group. Before BSC Nate spent 6 years in management consulting, half of them at Heath Advances focused on evaluating the commercial potential of emerging medical technology ranging from biotech and diagnostics to medical devices. Nate received his MBA from the Yale School of Management and his BA from Brown University.

Ron Bache is the President and CEO of Bache, Inc. and an Operating Partner with Invus Opportunities. Bache was previously the President and CEO of AqueSys, Inc., a venture capital backed startup. AqueSys developed the XEN Gel Stent, the world’s first minimally invasive ab-interno surgical procedure for the leading cause of irreversible blindness, glaucoma. Bache joined AqueSys in 2009 while it was within a technology incubator and had just begun first in man trials. During his seven years as CEO, Ron spun the company out of the incubator, hired a full global team, raised $77 million in capital, patented multiple inventions, successfully executed an FDA clinical trial, obtained FDA clearance, obtained CE mark, created a CAT III code and obtained coverage from Medicare and private payers, and successfully commercialized globally. AqueSys was acquired by Allergan in 2015 for $300 million upfront plus milestones and Bache became a strategic advisor to Allergan for the next two years.
Prior to joining AqueSys, Ron was a Global Vice President at Advanced Medical Optics, the spinout of Allergan Surgical, and is now Johnson & Johnson Vision. Bache had marketing responsibility for the global refractive surgery business which included excimer lasers, custom wavefront guided and standard LASIK procedures, femtosecond lasers, wavefront abberrometers, multifocal intraocular lenses, phakic intraocular lenses, corneal inlays, and mechanical microkeratomes. During his tenure, AMO became the world’s #1 refractive surgery company through approximately $2 billion in acquisitions, partnerships, and internal R&D. Prior to AMO, Bache held commercial positions at Kraft General Foods, Johnson & Johnson (IOLAB Pharmaceuticals), Novartis (CIBA Ophthalmics), and Allergan Surgical.
Bache earned his Bachelor of Science in Business Administration from the University of Southern California and has completed executive education programs at Stanford and Harvard Business School.